NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Is Up 6.1% After Raising 2026 Revenue Outlook And Turning Profitable
In February 2026, Arcutis Biotherapeutics reported fourth-quarter 2025 revenue of US$129.5 million and full-year revenue of US$376.07 million, moved to a Q4 net profit of US$17.4 million, and raised its 2026 net product revenue guidance to US$480 million–US$495 million while filing an omnibus shelf registration for multiple securities.
The results highlight how rapid uptake of ZORYVE across expanded indications, including pediatric use, is beginning to translate into improving profitability...